A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer.

Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, Hsu DH, Le Pecq JB, Lyerly HK. · 2005

Read A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. by Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, Hsu DH, Le Pecq JB, Lyerly HK. (2005) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc551593.txt.

Description

Morse and co-authors report a phase I trial in the Journal of Translational Medicine on a lung cancer vaccine. The vaccine uses dexosomes, tiny vesicles shed by dendritic cells. These parcels carry tumor antigens plus signals that wake immune cells. Thirteen patients with advanced non-small cell lung cancer enrolled. Their tumors expressed MAGE antigens, the vaccine's targets.

Nine patients finished four weekly doses, the authors report. Side effects stayed mild: mostly sore injection sites. Some patients held stable disease for many months. Skin tests and lab assays showed immune activation in a few. Making the vaccine proved feasible, so larger trials could follow.

Catalog record

CREATORMorse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, Hsu DH, Le Pecq JB, Lyerly HK.
YEAR2005
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC551593

Browse the full library · About the Tower of Babel